Enstilar in combination with Taltz for plaque psoriasis.
Full Title of Study: “Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients”
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: March 1, 2021
A single center study of 25 subjects to assess the addition of Enstilar Foam in patients receiving Taltz for ≥ 24 weeks with BSA between 3% and 8%.
- Drug: Enstilar
- topical Enstilar foam
Arms, Groups and Cohorts
- Experimental: Enstilar
- Enstilar foam
Clinical Trial Outcome Measures
- Body Surface Area 0 or 1
- Time Frame: 4 weeks
- Body surface area where 1 palm is equivalent to 1%. Endpoint will evaluate number of patiens who achieve body surface are 0 or 1.
Participating in This Clinical Trial
- Male or female adult ≥ 18 years of age; – Diagnosis of chronic plaque-type – Body Surface Area between 3%-8%. – Patient has been treated with Taltz for a minimum of 24 weeks – Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide. – Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination – Able and willing to give written informed consent prior to performance of any study-related procedures. Exclusion Criteria -˂3% or >8% BSA – Patient not receiving Taltz, or receiving Taltz <24 weeks – Any condition, which would place the subject at unacceptable risk if he/she were to participate in the study. – Pregnant or breast feeding, or considering becoming pregnant during the study. – Use of any investigational drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer). – Use of oral systemic medications for the treatment of psoriasis within 4 weeks. – Patient used other topical therapies to treat within 2 weeks of the Baseline Visit. – Patient received UVB phototherapy within 2 weeks of Baseline. – Patient received PUVA phototherapy within 4 weeks of Baseline. – Patient has a known hypersensitivity to the excipients of Enstilar® as stated in the label.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Psoriasis Treatment Center of Central New Jersey
- Eli Lilly and Company
- Provider of Information About this Clinical Study
- Overall Contact(s)
- Jerry Bagel, MD, 6094434500, firstname.lastname@example.org
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.